Stockreport

Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Tr...

Adial Pharmaceuticals, Inc  (ADIL) 
US:NASDAQ Investor Relations: adialpharma.com
PDF CHARLOTTESVILLE, Va., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutic [Read more]